100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
721970-37-2 & 1179992-99-4Moxifloxacin Related Compound F (Free Base)
● In Stock
| Catalogue No.: | VL106019 |
|---|---|
| CAS No.: | 721970-37-2 & 1179992-99-4 |
| Mol. Formula: | C22H26FN3O4 |
| Mol. Weight: | 415.46 g/mol |
Additional information on CAS 721970-37-2 & 1179992-99-4
Parent drug
MoxifloxacinIUPAC Name
1-Cyclopropyl-6-fluoro-8-methoxy-7-(1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acidInChI
InChI=1S/C22H26FN3O4/c1-24-7-3-4-12-9-25(11-17(12)24)19-16(23)8-14-18(21(19)30-2)26(13-5-6-13)10-15(20(14)27)22(28)29/h8,10,12-13,17H,3-7,9,11H2,1-2H3,(H,28,29)Pharmacopeial Synonyms
Moxifloxacin EP Impurity FSynonyms
N-Methyl Moxifloxacin; 1-Cyclopropyl-6-fluoro-1, 4-dihydro-8-methoxy-7-[(4aS, 7aS)-octahydro-1-methyl-6H-pyrrolo[3, 4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acidSmiles
CN1CCCC2C1CN(C2)C3=C(C=C4C(=C3OC)N(C=C(C4=O)C(=O)O)C5CC5)FPharmacopoeial Synonyms
Moxifloxacin EP Impurity FOther Synonyms
N-Methyl Moxifloxacin; 1-Cyclopropyl-6-fluoro-8-methoxy-7-(1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acidSmile
CN1CCCC2C1CN(C2)C3=C(C=C4C(=C3OC)N(C=C(C4=O)C(=O)O)C5CC5)FDescription
Moxifloxacin Related Compound F, also designated Moxifloxacin EP Impurity F or N-Methyl Moxifloxacin, is the N-methyl analog of the fluoroquinolone antibiotic moxifloxacin, corresponding to CAS 721970-37-2 and 1179992-99-4. Its molecular formula is C22H26FN3O4 and molecular weight is 415.46 g/mol. This basic quinolone impurity is typically associated with synthetic route variation or methylating conditions affecting the bicyclic amine side chain rather than oxidative degradation. Characterization generally requires LC-MS/MS for trace-level detection, supported by LC-HRMS and HPLC-UV comparison against the pharmacopeial reference profile. It is not a nitrosamine, but its presence is relevant to impurity profiling and specification setting under compendial and ICH impurity-control expectations.References
Al Omari, Mahmoud M. H., et al. “Moxifloxacin Hydrochloride.†Profiles of Drug Substances, Excipients and Related Methodology, 2014, pp. 299–431, https://doi.org/10.1016/b978-0-12-800173-8.00007-6. Miller, Darlene. “Review of Moxifloxacin Hydrochloride Ophthalmic Solution in the Treatment of Bacterial Eye Infections.†Clinical Ophthalmology, Mar. 2008, p. 77, https://doi.org/10.2147/opth.s1666. ? ?Request a Quote
"*" indicates required fields
Other products related to Moxifloxacin impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
